Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
FGEN is in the long-term up 67% in 5 years.
Description: FibroGen, Inc. discovers, develops, and commercializes drugs for anemia and pulmonary fibrosis. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was founded in 1993 and is headquartered in San Francisco, California.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||19.29%||Sales Growth - Q/Q||1.2%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-31.33%||ROE||-73.92%||ROI||-45.95%|
|Current Ratio||2.88||Quick Ratio||Long Term Debt/Equity||0.95||Debt Ratio||0.29|
|Gross Margin||Operating Margin||-281.76%||Net Profit Margin||-296.24%||Dividend Payout Ratio|
|Cash From Financing Activities||620 K||Cash From Investing Activities||4.55 M||Cash From Operating Activities||-42.19 M||Gross Profit|
|Net Profit||-46.37 M||Operating Profit||-44.72 M||Total Assets||435.54 M||Total Current Assets||155.4 M|
|Total Current Liabilities||53.96 M||Total Debt||111.65 M||Total Liabilities||250.92 M||Total Revenue||16.3 M|
|High 52 week||67.25||Low 52 week||35.14||Last close||35.77||Last change||-4.15%|
|RSI||26.06||Average true range||2.86||Beta||1.53||Volume||241.17 K|
|Simple moving average 20 days||-18.87%||Simple moving average 50 days||-27.97%||Simple moving average 200 days||-30.35%|
|Performance Week||-1.7%||Performance Month||-22.48%||Performance Quart||-38.85%||Performance Half||-12.05%|
|Performance Year||-32%||Performance Year-to-date||-22.71%||Volatility daily||5.57%||Volatility weekly||12.46%|
|Volatility monthly||25.54%||Volatility yearly||88.49%||Relative Volume||223.58%||Average Volume||843.49 K|
|New High||New Low|
2019-08-20 16:47:08 | Nabriva NBRV Gains FDA Approval for Pneumonia Drug Xenleta
2019-08-19 17:55:09 | Nabriva NBRV Aims to Resubmit Contepo NDA in Q4
2019-08-15 01:15:29 | Fibrogen Inc FGEN CEO Thomas B Neff Sold $1.8 million of Shares
2019-08-14 09:51:01 | Tilray TLRY Catches Eye: Stock Jumps 8.4%
2019-08-13 09:44:22 | FibroGen NASDAQ:FGEN Has A Pretty Healthy Balance Sheet
2019-08-09 23:07:18 | FibroGen Inc FGEN Q2 2019 Earnings Call Transcript
2019-08-09 17:03:26 | Edited Transcript of FGEN earnings conference call or presentation 8-Aug-19 9:00pm GMT
2019-08-08 20:00:12 | FibroGen FGEN Q2 Earnings and Revenues Top Estimates
2019-08-01 19:24:01 | FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019
2019-07-30 10:38:02 | Earnings Preview: FibroGen FGEN Q2 Earnings Expected to Decline
2019-07-26 19:15:02 | Fibrogen Inc FGEN CEO Thomas B Neff Sold $1.9 million of Shares
2019-07-10 06:00:56 | Shareholders Are Thrilled That The FibroGen NASDAQ:FGEN Share Price Increased 165%
2019-06-18 08:04:03 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-06-13 11:20:03 | Here’s What Hedge Funds Think About FibroGen Inc FGEN
2019-06-13 08:04:59 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-06-11 08:06:10 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-06-10 08:05:09 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-06-10 07:00:00 | FibroGen to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
2019-06-06 08:04:35 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-06-05 17:00:00 | FibroGen Appoints Suzanne Blaug to Board of Directors
2019-06-04 08:02:42 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-05-16 08:54:12 | Implied Volatility Surging for FibroGen FGEN Stock Options
2019-05-13 06:26:03 | FibroGen Inc FGEN Q1 2019 Earnings Call Transcript
2019-05-10 18:11:18 | Edited Transcript of FGEN earnings conference call or presentation 9-May-19 9:00pm GMT
2019-05-10 14:29:00 | Here's Why FibroGen Fell as Much as 26.6% Today
2019-05-10 12:50:08 | FibroGen News: Why FGEN Stock Is Plummeting Today
2019-05-09 20:25:12 | FibroGen FGEN Reports Q1 Loss, Tops Revenue Estimates
2019-05-09 19:19:30 | FibroGen: 1Q Earnings Snapshot
2019-05-09 16:44:50 | FibroGen Reports First Quarter 2019 Financial Results
2019-05-07 08:02:44 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-05-06 17:00:00 | FibroGen to Report First Quarter 2019 Financial Results
2019-05-02 14:34:06 | Zoetis ZTS Earnings Beat Estimates in Q1, Revenues Miss
2019-05-01 10:33:02 | Analysts Estimate FibroGen FGEN to Report a Decline in Earnings: What to Look Out for
2019-04-30 08:02:12 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-04-26 09:18:26 | Here’s What Hedge Funds Think About FibroGen Inc FGEN
2019-04-10 10:30:02 | Akebia Expands Vadadustat Licensing Deal With Vifor Pharma